David Wayne Nichols - 19 Apr 2021 Form 4/A - Amendment Insider Report for Magenta Therapeutics, Inc. (DNTH)

Role
Chief Technical Officer
Signature
/s/ Cindy Driscoll, Attorney-in-Fact for David Nichols
Issuer symbol
DNTH
Transactions as of
19 Apr 2021
Net transactions value
$0
Form type
4/A - Amendment
Filing time
17 May 2021, 17:07:04 UTC
Date Of Original Report
20 Apr 2021
Next filing
16 Sep 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MGTA Stock Option (Right to Buy) Award $0 +175,000 $0.000000 175,000 19 Apr 2021 Common Stock 175,000 $10.50 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option shall vest and become exerciseable over four years, with 25% of this option vesting on April 19, 2022, and the remainder vesting in 36 equal monthly installments thereafter.
F2 This amendment has been filed to revise the vesting terms of Mr. Nichols' stock option, which were reported incorrectly on Mr. Nichols' prior Form 4. The corrected vesting schedule is included in Footnote 1 above.